Search results
Results From The WOW.Com Content Network
Duration of overall response The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an immuno-oncology drug.
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
The concept is used in cancer survival analyses. [citation needed] Many cancer studies aim to assess the time between two events of interest, such as from treatment to remission, treatment to relapse, or diagnosis to death. This duration is generically called survival time, even if the end point is not death. [1]
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
The greatest risk period for the occurrence of infection is in the initial few months after the start of new drug therapy, since many drug therapies further suppress the normal immune response. [31] Infections (and "adverse events" for all diseases) are graded by a standardized scale. [32]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Length time bias in cancer screening. Screening appears to lead to better survival even when actually no one lived any longer. Length time bias (or length bias) is an overestimation of survival duration due to the relative excess of cases detected that are asymptomatically slowly progressing, while fast progressing cases are detected after giving symptoms.